Dendreon posts $4.59 million December loss from operations; revenue up

By Caroline Salls

Pittsburgh, Jan. 21 – Dendreon Corp. reported a $4.59 million loss from operations for December on $28.78 million in total revenue, according to its monthly operating report filed with the Securities and Exchange Commission.

In comparison, the company posted $9.96 million of operating income for November on total revenue of $21.97 million.

The net loss for December was $4.96 million, narrowing from $8.41 million of November net income.

The company listed $101.48 million in cash and cash equivalents as of Dec. 31, up from $78.33 million at the end of November.

Dendreon, a Seattle-based biotechnology company that focuses on novel therapeutics to enhance cancer treatment options, filed for bankruptcy on Nov. 10 in the U.S. Bankruptcy Court for the District of Delaware. The Chapter 11 case number is 14-12515.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.